• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

系统分析 LTBR 在人类癌症中的预后价值和免疫功能。

Systematic analysis of the prognostic value and immunological function of LTBR in human cancer.

机构信息

Department of Orthopedic and Trauma Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.

Department of Cardiovascular Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.

出版信息

Aging (Albany NY). 2024 Jan 3;16(1):129-152. doi: 10.18632/aging.205356.

DOI:10.18632/aging.205356
PMID:38175686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10817409/
Abstract

Lymphotoxin beta receptor (LTBR) is a positive T cell proliferation regulator gene. It is closely associated with the tumor immune microenvironment. However, its role in cancer and immunotherapy is unclear. Firstly, the expression level and prognostic value of LTBR were analyzed. Secondly, the expression of LTBR in clinical stages, immune subtypes, and molecular subtypes was analyzed. The correlation between LTBR and immune regulatory genes, immune checkpoint genes, and RNA modification genes was then analyzed. Correlations between LTBR and immune cells, scores, cancer-related functional status, tumor stemness index, mismatch repair (MMR) genes, and DNA methyltransferase were also analyzed. In addition, we analyzed the role of LTBR in DNA methylation, mutational status, tumor mutation burden (TMB), and microsatellite instability (MSI). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were used to explore the role of LTBR in pan-cancer. Finally, the drugs associated with LTBR were analyzed. The expression of LTBR was confirmed using quantitative real-time PCR and Western blot. LTBR is significantly overexpressed in most cancers and is associated with low patient survival. In addition, LTBR expression was strongly correlated with immune cells, score, cancer-related functional status, tumor stemness index, MMR genes, DNA methyltransferase, DNA methylation, mutational status, TMB, and MSI. Enrichment analysis revealed that LTBR was associated with apoptosis, necroptosis, and immune-related pathways. Finally, multiple drugs targeting LTBR were identified. LTBR is overexpressed in several tumors and is associated with a poor prognosis. It is related to immune-related genes and immune cell infiltration.

摘要

淋巴毒素β受体 (LTBR) 是阳性 T 细胞增殖调节基因。它与肿瘤免疫微环境密切相关。然而，其在癌症和免疫治疗中的作用尚不清楚。首先，分析了 LTBR 的表达水平和预后价值。其次，分析了 LTBR 在临床分期、免疫亚型和分子亚型中的表达。然后分析了 LTBR 与免疫调节基因、免疫检查点基因和 RNA 修饰基因的相关性。分析了 LTBR 与免疫细胞、评分、癌症相关功能状态、肿瘤干性指数、错配修复 (MMR) 基因和 DNA 甲基转移酶的相关性。此外，还分析了 LTBR 在 DNA 甲基化、突变状态、肿瘤突变负担 (TMB) 和微卫星不稳定性 (MSI) 中的作用。基因本体论 (GO)、京都基因与基因组百科全书 (KEGG) 和基因集富集分析 (GSEA) 用于探索 LTBR 在泛癌中的作用。最后，分析了与 LTBR 相关的药物。使用定量实时 PCR 和 Western blot 验证了 LTBR 的表达。LTBR 在大多数癌症中显著过表达，与患者生存率低相关。此外，LTBR 表达与免疫细胞、评分、癌症相关功能状态、肿瘤干性指数、MMR 基因、DNA 甲基转移酶、DNA 甲基化、突变状态、TMB 和 MSI 密切相关。富集分析表明，LTBR 与细胞凋亡、坏死性凋亡和免疫相关途径有关。最后，鉴定了多种针对 LTBR 的药物。LTBR 在几种肿瘤中过表达，与预后不良相关。它与免疫相关基因和免疫细胞浸润有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/8cb3db738189/aging-16-205356-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/ada343ead12e/aging-16-205356-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/83479588d932/aging-16-205356-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/a699927a33fb/aging-16-205356-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/49b60df2f6c4/aging-16-205356-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/be8ecb9319d6/aging-16-205356-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/2dff0aa77f72/aging-16-205356-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/dfe21286d070/aging-16-205356-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/a9f04d995315/aging-16-205356-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/e0a068062866/aging-16-205356-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/184024d8c222/aging-16-205356-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/abdf3f0b245b/aging-16-205356-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/8cb3db738189/aging-16-205356-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/ada343ead12e/aging-16-205356-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/83479588d932/aging-16-205356-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/a699927a33fb/aging-16-205356-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/49b60df2f6c4/aging-16-205356-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/be8ecb9319d6/aging-16-205356-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/2dff0aa77f72/aging-16-205356-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/dfe21286d070/aging-16-205356-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/a9f04d995315/aging-16-205356-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/e0a068062866/aging-16-205356-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/184024d8c222/aging-16-205356-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/abdf3f0b245b/aging-16-205356-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428a/10817409/8cb3db738189/aging-16-205356-g012.jpg

相似文献

1
Systematic analysis of the prognostic value and immunological function of LTBR in human cancer.系统分析 LTBR 在人类癌症中的预后价值和免疫功能。
Aging (Albany NY). 2024 Jan 3;16(1):129-152. doi: 10.18632/aging.205356.
2
Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3.潜在肿瘤诊断和预后生物标志物P4HA3的全癌系统分析
Front Genet. 2023 Mar 22;14:1045061. doi: 10.3389/fgene.2023.1045061. eCollection 2023.
3
RecQ mediated genome instability 2 (): a potential prognostic and immunological biomarker for pan-cancers.RecQ 介导的基因组不稳定性 2（）：一种潜在的泛癌预后和免疫生物标志物。
Aging (Albany NY). 2022 May 12;14(9):4107-4136. doi: 10.18632/aging.204076.
4
HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.HHLA2 作为一种潜在的预后和免疫生物标志物，与泛癌中的肿瘤微环境相关。
Biomed Res Int. 2022 Feb 23;2022:3924400. doi: 10.1155/2022/3924400. eCollection 2022.
5
Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.浅析 NAAA 在泛癌中的预后价值和免疫学作用。
Front Immunol. 2022 Jan 6;12:812713. doi: 10.3389/fimmu.2021.812713. eCollection 2021.
6
Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.系统性泛癌症分析确定 cuproptosis 相关基因 DLAT 为免疫和预后生物标志物。
Aging (Albany NY). 2023 May 17;15(10):4269-4287. doi: 10.18632/aging.204728.
7
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.鉴定胃癌中与铜死亡相关的亚型，构建预后模型和肿瘤微环境景观。
Front Immunol. 2022 Nov 21;13:1056932. doi: 10.3389/fimmu.2022.1056932. eCollection 2022.
8
Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.基于多组学数据的膜联蛋白家族在泛癌中预后、免疫浸润和免疫治疗疗效的证据。
Funct Integr Genomics. 2023 Jun 26;23(3):211. doi: 10.1007/s10142-023-01106-z.
9
Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.胃癌中 m6A 相关 lncRNAs 的肿瘤免疫微环境综合分析与预后评估。
BMC Cancer. 2022 Mar 24;22(1):316. doi: 10.1186/s12885-022-09377-8.
10
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.系统泛癌症分析鉴定 TREM2 为一种免疫和预后生物标志物。
Front Immunol. 2021 Feb 17;12:646523. doi: 10.3389/fimmu.2021.646523. eCollection 2021.

引用本文的文献

1
Reduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway.淋巴毒素β受体的减少通过MDMX-p53途径诱导细胞衰老。
Cell Death Discov. 2025 Aug 29;11(1):416. doi: 10.1038/s41420-025-02708-1.
2
Identification of therapeutic targets for neonatal respiratory distress: A systematic druggable genome-wide Mendelian randomization.新生儿呼吸窘迫治疗靶点的鉴定：全基因组范围内可成药的系统性孟德尔随机化研究
Medicine (Baltimore). 2025 May 16;104(20):e42411. doi: 10.1097/MD.0000000000042411.
3
Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.

本文引用的文献

1
LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance.LRP1B通过NCSTN/PI3K/AKT信号轴抑制肝癌进展并影响阿霉素耐药性。
Genes Dis. 2022 Nov 23;10(5):2082-2096. doi: 10.1016/j.gendis.2022.10.021. eCollection 2023 Sep.
2
Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma.将单细胞分析和机器学习相结合，创建基于糖基化的基因标志物，用于葡萄膜黑色素瘤的预后预测。
Front Endocrinol (Lausanne). 2023 Mar 23;14:1163046. doi: 10.3389/fendo.2023.1163046. eCollection 2023.
3
利用生物信息学分析和实验探索CDCA4在肝细胞癌中的作用。
Medicine (Baltimore). 2024 May 3;103(18):e38028. doi: 10.1097/MD.0000000000038028.
Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
鞘脂标志物的预后特征：了解免疫图谱及其在预测肝癌免疫治疗反应和结局中的作用。
Front Immunol. 2023 Mar 17;14:1153423. doi: 10.3389/fimmu.2023.1153423. eCollection 2023.
4
T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis integrating single-cell RNA-seq and bulk RNA-sequencing.T 细胞耗竭特征可描绘免疫图谱并整合单细胞 RNA 测序和批量 RNA 测序预测 HCC 预后。
Front Immunol. 2023 Mar 15;14:1137025. doi: 10.3389/fimmu.2023.1137025. eCollection 2023.
5
Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity.昼夜节律相关基因指数：预测头颈部鳞状细胞癌的预后、免疫治疗疗效和化疗敏感性的指标。
Front Immunol. 2023 Mar 10;14:1091218. doi: 10.3389/fimmu.2023.1091218. eCollection 2023.
6
Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.鉴定卵巢癌中与铜代谢相关的亚型并建立预后模型。
Front Endocrinol (Lausanne). 2023 Mar 6;14:1145797. doi: 10.3389/fendo.2023.1145797. eCollection 2023.
7
Lactate in the tumor microenvironment: A rising star for targeted tumor therapy.肿瘤微环境中的乳酸：靶向肿瘤治疗的一颗新星。
Front Nutr. 2023 Feb 16;10:1113739. doi: 10.3389/fnut.2023.1113739. eCollection 2023.
8
Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.胶质母细胞瘤和帕金森病中神经营养因子相关基因特征的鉴定和验证。
Front Immunol. 2023 Feb 7;14:1090040. doi: 10.3389/fimmu.2023.1090040. eCollection 2023.
9
NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation.NCAPG2 可能是一种免疫和预后生物标志物：从泛癌分析到胰腺癌验证。
Front Immunol. 2023 Jan 27;14:1097403. doi: 10.3389/fimmu.2023.1097403. eCollection 2023.
10
Exosomes: A potential tool for immunotherapy of ovarian cancer.外泌体：卵巢癌免疫治疗的潜在工具。
Front Immunol. 2023 Jan 18;13:1089410. doi: 10.3389/fimmu.2022.1089410. eCollection 2022.